Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.57 |
| ▸ | HTR3A | P46098 | 3/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.57 |
| ▸ | HTR3B | O95264 | 2/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911529 | 0.88 | TGFBR1 (0.57) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL940806 | 0.86 | TGFBR1 (0.56) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14650779 | 0.84 | UBE2T (0.51) | DHFRHRH3 | |
| SCHEMBL22638127 | 0.83 | CHRNB2 (0.56) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL27837554 | 0.83 | UBE2T (0.50) | DHFRHRH3 | |
| SCHEMBL3920532 | 0.81 | DHFR (0.48) | DHFRHRH3 | |
| SCHEMBL10833518 | 0.80 | HTR1A (0.59) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL24921472 | 0.80 | KDM4E (0.61) | DHFR | |
| SCHEMBL1472886 | 0.80 | SCN9A (0.49) | ADRB1PLD1 | |
| SCHEMBL25187137 | 0.80 | SCN9A (0.46) | ADRB1HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-11612599-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2023-03-28 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-1853582-B1 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1853582-B1 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101128455-A | Heterocyclylamide-substituted imidazoles | BAYER HEALTHCARE AG (DE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1853582-A2 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AiCuris GmbH & Co. KG (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089664-A2 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2006-08-31 | — | — | WO | disclosed |
| US-5650411-A | BACTERICIDES FOR HELICOBACTER DISEASES AND BACTERIA RESISTANCE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-22 | — | — | US | disclosed |
| EP-0684821-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018978-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612599-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | ADRB1 2255/4885HTR3A 3259/4885HTR3E 3291/4885 |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885HTR3A 3631/4885HTR3E 4178/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | ADRB1 746/4885HTR3A 3484/4885HTR3E 3135/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885HTR3A 3631/4885HTR3E 4178/4885 |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | TPMT, TYMP, PAICS | ADRB1 3626/4885HTR3A 1957/4885HTR3E 1086/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | ADRB1 2570/4885HTR3A 3631/4885HTR3E 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.